Study On Borrelidin,A Secondary Metabolite Produced By Streptomyces Sp.BOR-0331

In this study, the secondary metabolites of Streptomyces BOR-0331 were isolated to screen compounds with novel structures or new bioactivity.Angiogenesis plays an important role in the process of tumor growth and blocking this process is a therapy with great prospect. Currently,most of the clinical inhibitors are antibodys, so the researches in small-molecule angiogenesis inhibitors is attracting. In our researching work, a compound with antibacterial activity in the fermentation broth produced by Streptomyces BOR-0331 was found. The TLC results show that the active component could be a macrolide. Because of the low fermentation titer,ultraviolet mutagenesis and response surface method(RSM) were used to increase the titer of target compound to 35.3mg/L. Serial processes were used to get the pure target compound such as macroporous resin column chromatography, silica gel chromatography, C18 chromatography, Sephadex LH-20 gel column chromatography, etc. The chemical structures of the compound determined by UV, IR, MS and NMR spectra were identified to the macrolide antibiotic borrelidin.Borrelidin showed multiple bioactivities,and could be a lead compound as vascular endothelial growth factor(VEGF)inhibitor, antitumor drug, antibiotic.